Interstitial Cystitis Drugs Market Size to Exceed USD 428.3 Mn by 2032

The Interstitial Cystitis Drugs Market, estimated at USD 268.5 Mn in 2025, is expected to exhibit a CAGR of 6.9% and reach USD 428.3 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key market players are focusing on adopting various growth strategies, such as conducting clinical trials and others, for patients suffering from interstitial cystitis, which in turn is expected to drive market growth over the forecast period. For instance, in March 2022, Allergan, a subsidiary of Abbive, Inc., a pharmaceutical company, initiated a clinical trial to study how safe and effective BOTOX (onabotulinumtoxinA) is in treating interstitial cystitis/bladder pain syndrome (IC/BPS), which is currently in phase 2 of the clinical trial and is actively recruiting patients.

Global Interstitial Cystitis Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

The COVID-19 pandemic has affected several markets across the globe and is also expected to hamper demand and supply in the global interstitial cystitis drugs market. The COVID-19 pandemic has affected the demand and supply of viral conjunctivitis drugs market in three main ways: by directly affecting production and demand; by creating disruptions in distribution channels; and by having a financial impact on firms and financial markets. The supply chain and manufacturing activities of viral conjunctivitis drugs in India, China, and the U.S. are disrupted due to nationwide lockdowns. Whereas countries, such as Saudi Arabia, the UAE, Egypt, and others, faced problems with regards to the transportation of drugs from one place to another.

Global Interstitial Cystitis Drugs Market: Key Developments

In December 2022, Imbrium Therapeutics L.P., a subsidiary of Purdue Pharma L.P., a pharmaceutical company, announced that the first patient visit has been completed in the Phase 1 clinical study evaluating intravesical (into the bladder) IMB-150 (also known as LYT-503) as a potential non-opioid treatment for female patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). IMB-150, developed by PureTech, a fullservice digital marketing agency, applying its AlivioTM technology platform, is a novel formulation of lidocaine, and the clinical development program is called GainMe-IC. IMB-150 was licensed from PureTech.

In April 2021, Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development, announced the grant of a new patent (application number 16/190,450) by the U.S. Patent and Trademark Office. This patent covers the method for the development of a cannabinoid-based treatment that is used for interstitial cystitis.

In January 2021, Kyorin Pharmaceutical Co., Ltd. , a wholly owned subsidiary of KYORIN Holdings, Inc., a pharmaceutical company, received approval from the Ministry of Health, Labour, and Welfare (hereinafter “MHLW”) as of January 22, 2021, to market the interstitial cystitis “Zymso Intravesical Solution 50%” (hereinafter “Zymso”) in Japan. Zymso is an intravesical infusion containing 50% (w/w) of dimethyl sulfoxide, and its phase III clinical trial (a multicenter, randomized, double-blind, placebo-controlled, parallel-group study) in 96 Japanese patients with interstitial cystitis was conducted, and its efficacy and safety were evaluated and approved.

In September 2020, according to the report published in National Center for Biotechnology Information, reported that, autologous platelet-rich plasma’s (PRP) popularity as a therapy is increasing. Repeated intravenous injections of autologous platelet-rich plasma (PRP) have been shown to improve symptoms in patients with interstitial cystitis/bladder pain syndrome (IC/BPS). The urine biomarkers such as NGF, PDGF-AB, MMP-13, and VEGF showed significant changes after three PRP injections. These findings indicate that PRP can alter the bladder environment and alleviate inflammation in diseased bladders.

Browse 44 Market Data Tables and 36 Figures spread through 199 Pages and in-depth TOC on “Global Interstitial Cystitis Drugs Market”- Forecast to 2030, Global Interstitial Cystitis Drugs Market, By Drug Class [Non-steroidal Anti-inflammatory Drugs, Tricyclic Antidepressants, Pentosan Polysulfate Sodium (Elmiron), Dimethyl Sulfoxide (DMSO) and Others (Anti-histamines, etc.)], By Type [Non-ulcerative and Ulcerative], By Route of Administration [Oral  and Intravesical], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies], and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/interstitial-cystitis-drugs-market-4488

Key Takeaways of the Global Interstitial Cystitis Drugs Market:

• The global interstitial cystitis drugs market is expected to exhibit a CAGR of 6.9% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global interstitial cystitis drugs market.
• Among drug class, the pentosan polysulfate sodium (Elmiron) segment is expected to hold a dominant position in the global interstitial cystitis drugs market during the forecast period, and this is attributed to the rising adoption of various inorganic growth strategies, such as collaboration and others among the market players, which in turn is expected to fuel the segmental growth over the forecast period. For instance, in December 2021, Hyloris Pharmaceuticals SA, a specialty biopharma company, committed to addressing unmet medical needs through reinventing  existing medications, announced  that it had entered into a strategic collaboration with Vaneltix Pharma, Inc., a pharmaceutical company, for the development  and  commercialization  of  Alenura  as  first-line  drug treatment for acute  pain in  interstitial  cystitis /bladder  pain  syndrome (IC/BPS). Alenura is a patented, clinical-stage bladder instillation product candidate that combines lidocaine, a well-established anaesthetic, in a new alkalinized form with heparin, a component of mucous membranes.
• Among regions, North America is expected to be the dominant region in the global interstitial cystitis drugs market, owing to the key players focus on research and development activities for the treatment of patients suffering from interstitial cystitis/bladder pain syndrome (IC/BPS). For instance, on June 22, 2023, Hyloris Pharmaceuticals SA announced that they had enrolled their first patient in a 4-arm Phase 2 trial of AlenuraTM, comparing the product candidate to both of its individual components (heparin and lidocaine)3 as well as placebo. AlenuraTM is a patented, innovative, clinical-stage bladder instillation product candidate that combines lidocaine, a well-established anesthetic, in a new alkalinized form with heparin, a glycoso-amino-glycan (GAG), a component of bladder mucous membranes.
• Major players operating in the global interstitial cystitis drugs market are AbbVie Inc., Hyloris Pharmaceuticals SA, TAGCyx Biotechnologies, KYORIN Pharmaceutical Co., Ltd., PureTech Health, Vaneltix, Red Leaf Medical Inc., Bayer AG, Eli Lilly and Co, Johnson & Johnson (Janssen Pharmaceuticals), Mylan NV (Viatris Inc.), Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and ImprimisRx (Harrow Health, Inc.)